UNSPSC 51171605: Lactulose

This classification denotes a laxative and disaccharide, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9U7D5QH5AE. European Medicines Agency schedules Lactulose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08386MIG. Lactulose generally arises in the molecular formula C12H22O11.

UNSPSC 51171605 Lactulose, a Commodity code, encompasses pharmaceutical products that state and local governments procure for correctional health, pharmacy benefit programs, and multistate cooperative purchasing arrangements. Recent solicitations show demand for lactulose specifically as part of broader pharmaceutical procurement — including generic multi-source drugs, OTC products, and direct-to-manufacturer prescription programs — but state and local buyers are acquiring lactulose primarily through high-volume cooperative purchasing vehicles and correctional-health specimen testing and pharmacy benefit contracts rather than as a standalone item. Issuing bodies include county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions.

Recent activity spans Texas and Minnesota. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term with three optional one-year renewals; while this opportunity focuses on drug testing rather than lactulose procurement per se, it reflects state correctional health infrastructure where lactulose and related pharmaceuticals are consumed. The Texas Health and Human Services Commission posted RFI No. HHS0017013 in late March 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling state-level interest in alternative pharmacy distribution models that could reshape lactulose sourcing. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon; lactulose as a generic pharmaceutical would fall within this scope, with awarded vendors subject to a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation. Contract term for the MMCAP RFP is two years for new responders with optional extensions, or alignment with existing agreement expiration dates through June 30, 2028, for incumbent responders.